Direct randomized evidence for systemic targeted therapies in prurigo nodularis: a systematic review and meta-analysis
- 1The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine , , ,
- 2Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine) , , ,
Abstract
Background
Systemic targeted therapies are reshaping treatment for prurigo nodularis (PN), but the timing of clinically meaningful benefits and the strength of supporting evidence remain unclear. We synthesized direct placebo-controlled evidence by outcome and follow-up time, distinguishing replicated phase 3 evidence from preliminary signals.Methods
PubMed, Embase, Web of Science, CENTRAL, and ClinicalTrials.gov were searched from inception to June 30, 2026, for randomized controlled trials of systemic targeted therapies for PN. Compatible outcomes were pooled separately at prespecified time points using random-effects models. The primary outcome was a ≥ 4-point reduction in weekly average Worst Itch or Peak Pruritus Numerical Rating Scale scores. Secondary outcomes included Investigator's Global Assessment (IGA) success, dual response, sleep, quality of life, psychological outcomes, and safety. Risk of bias and certainty were assessed using RoB 2 and GRADE.Results
Eleven trials involving 1,623 participants evaluated six therapies. Itch response favored active treatment at weeks 4 (RR 4.76, 95% CI 3.01-7.55), 12 (2.67, 1.43-5.00), 16 (3.32, 2.57-4.29), and 24 (3.09, 2.18-4.38), whereas the week 8 estimate was imprecise (1.73, 0.94-3.21). IGA success was supported from week 8 onward. Nemolizumab improved sleep response by week 4, and two phase 3 dupilumab trials showed a week 24 dual-response benefit (RR 3.98, 2.31-6.85). Treatment-emergent adverse events were modestly more frequent with active treatment (RR 1.14, 1.06-1.24), while serious adverse events and discontinuations did not clearly increase. The most robust evidence came from replicated phase 3 programs of dupilumab and nemolizumab.Conclusion
Replicated randomized evidence supports clinically meaningful improvements in itch and lesion outcomes with dupilumab and nemolizumab. Symptomatic benefits may emerge earlier than lesion responses, but this pattern should be interpreted cautiously because evidence across time points derives from limited, partly non-overlapping trial sets. Comparative treatment ranking is not supported, and longer-term data are needed to define rare, delayed, and agent-specific harms.Systematic review registration
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261445753, identifier CRD420261445753.
Related
- Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses
- Systemic Glucose-Lowering Therapies and Periodontal and Peri-Implant Outcomes in Adults With Type 2 Diabetes Mellitus: A Systematic Review.
- Effects of Bioactive Compound Supplementation on Insulin Resistance and Systemic Inflammation in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Clinical Evidence of Orally Administered Herbal Preparations for Supportive Cancer Care: A PRISMA Systematic Review of Randomized Clinical Trials (1990–2026)
- Timing of First Systemic Antibiotic Administration and Risk of Deep Infection in Adults with Open Long-Bone Fractures: A Systematic Review and Threshold-Specific Evidence Synthesis
BibTeX
@article{yu2026direct,
title = {{Direct randomized evidence for systemic targeted therapies in prurigo nodularis: a systematic review and meta-analysis}},
author = {Yue Yu and Siqi Li and Weiwen Chen and Xinsheng Chen},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1942040},
url = {https://europepmc.org/article/PMC/PMC13717402},
note = {CC BY},
}
RIS
TY - JOUR
TI - Direct randomized evidence for systemic targeted therapies in prurigo nodularis: a systematic review and meta-analysis
AU - Yue Yu
AU - Siqi Li
AU - Weiwen Chen
AU - Xinsheng Chen
PY - 2026
DA - 2026/10/15
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1942040
UR - https://europepmc.org/article/PMC/PMC13717402
AB - Background Systemic targeted therapies are reshaping treatment for prurigo nodularis (PN), but the timing of clinically meaningful benefits and the strength of supporting evidence remain unclear. We synthesized direct placebo-controlled evidence by outcome and follow-up time, distinguishing replicated phase 3 evidence from preliminary signals.Methods PubMed, Embase, Web of Science, CENTRAL, and ClinicalTrials.gov were searched from inception to June 30, 2026, for randomized controlled trials of systemic targeted therapies for PN. Compatible outcomes were pooled separately at prespecified time points using random-effects models. The primary outcome was a ≥ 4-point reduction in weekly average Worst Itch or Peak Pruritus Numerical Rating Scale scores. Secondary outcomes included Investigator's Global Assessment (IGA) success, dual response, sleep, quality of life, psychological outcomes, and safety. Risk of bias and certainty were assessed using RoB 2 and GRADE.Results Eleven trials involving 1,623 participants evaluated six therapies. Itch response favored active treatment at weeks 4 (RR 4.76, 95% CI 3.01-7.55), 12 (2.67, 1.43-5.00), 16 (3.32, 2.57-4.29), and 24 (3.09, 2.18-4.38), whereas the week 8 estimate was imprecise (1.73, 0.94-3.21). IGA success was supported from week 8 onward. Nemolizumab improved sleep response by week 4, and two phase 3 dupilumab trials showed a week 24 dual-response benefit (RR 3.98, 2.31-6.85). Treatment-emergent adverse events were modestly more frequent with active treatment (RR 1.14, 1.06-1.24), while serious adverse events and discontinuations did not clearly increase. The most robust evidence came from replicated phase 3 programs of dupilumab and nemolizumab.Conclusion Replicated randomized evidence supports clinically meaningful improvements in itch and lesion outcomes with dupilumab and nemolizumab. Symptomatic benefits may emerge earlier than lesion responses, but this pattern should be interpreted cautiously because evidence across time points derives from limited, partly non-overlapping trial sets. Comparative treatment ranking is not supported, and longer-term data are needed to define rare, delayed, and agent-specific harms.Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261445753, identifier CRD420261445753.
SN - 2296-858X
ER -